Bristol Myers eyes major cuts; That $1B AI startup; Pharma reacts to China bill; Q1 earnings highlights; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

It’s been quite a week with some big scoops from the End­points team, on top of what is shap­ing up to be an in­ter­est­ing earn­ings sea­son. See you next week as we track the biggest themes emerg­ing from me­dia and in­vestor calls.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.